Valneva Stock Declines 8% Over One Month and Erases Part of Its Rebound

A Decline That Brings the Stock Below Its 20-Day Moving Average

Valneva loses 2.23% to €2.72 during trading, compared to a close of €2.79 the previous day, in an SBF 120 that itself declines 0.77%. This decline adds to a weekly loss of 4.76% and a monthly loss of 8.16%, erasing a significant portion of the rebound accumulated over the quarter. The stock thus remains at the bottom of the index ranking, without reaching the most penalized values of the day. The technical configuration reflects this tension.

The price has fallen below the MA20 at €2.86 (gap of -4.76%), signaling a short-term reversal since the early September peak. Conversely, the MA50 at €2.59 remains below the price, with a positive gap of 5.17%: this floor provides an intermediate reference point, especially as the identified support at €2.46 remains at a distance. The RSI at 50 remains strictly neutral, without oversold or overbought signals, which leaves the momentum open in both directions.

Positive Quarterly Performance But Operational Risks Weighing on Visibility

On the fundamental side, Valneva displayed, when publishing its first half 2026 results on August 13, a quarterly performance that remained positive over twelve weeks despite an unfavorable geopolitical context for travel. The company had then confirmed its 2026 outlook, with a revenue target of €147.5 million, while adopting a cautious tone. Among the risks highlighted on this occasion were the dependence on IXIARO deliveries to the U.S. Department of Defense and the refocusing of IXCHIQ on endemic markets, which weigh on short-term commercial visibility.

Regarding prospects, Valneva anticipated in this same publication an improvement in gross margins in the second half, following non-recurring items that had increased the burden in H1 2026. Regulatory decisions on the LB6V vaccine candidate against Lyme disease, developed with Pfizer, are expected within twelve months following this publication. Resistance at €3.07, already tested in early September without being broken, remains the natural objective in case of a recovery, while support at €2.46 constitutes the floor to watch if the decline were to intensify.